F2G

PITCH

F2G believes that its novel agent, olorofim, and subsequent agents, will address some of the many challenges which face the treating physician and the patient with invasive fungal infections.

Based in

Manchester

Created in

> Website

LATEST INVESTMENT

#HealthTech 08.2020

F2G

£46.7M

Cowen Healthcare Investments, Novo Holdings, Morningside Ventures, Brace Pharma Capital, Advent Life Sciences